Company intelligence / Profile preview
Aidea Pharma
Yangzhou, Jiangsu, Chinaen.aidea.com.cn ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Aidea Pharma has successfully developed and commercialized two Class 1 innovative anti-HIV/AIDS drugs—ainuovirine tablets and ainuomiti tablets. The company maintains a robust pipeline with 18 ongoing research projects spanning antivirals, inflammation, and stroke. It holds over 15 invention patents with more than 30 authorized patents overall. Its human urinary protein business generates stable cash flow while supporting innovation in new drug development.
- Therapeutic areas
- ImmunologyGastroenterologyCardiovascularNeurologyInfectious Diseases
- Modalities
- Small moleculeProteinBiologic
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Aidea Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aidea Pharma.